ArriVent BioPharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$177.5M | -$94.3M | -$74.6M |
| Operating expenses | $177.5M | $94.3M | $74.6M |
| Cash from operations | -$160.6M | -$70.2M | -$55.8M |
| Total assets | $333.2M | $274.9M | $163.1M |
| Total liabilities | $25.9M | $17.3M | $11.8M |
Shares outstanding 46.6M · Free float 82.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.